Download Sample, Autoimmune Disorders & Demand for Blood Component Boost the Market Growth
The number of people suffering from of chronic diseases such as cancer and autoimmune disorders is anticipated to rise, driving market growth. According to the National Stem Cell Foundation (NSCF), approximately 80 different autoimmune disorders affect around 4% of the world's population. Autoimmune diseases are third among the leading causes of chronic diseases in the US. According to Johns Hopkins Medicine Pathology, autoimmune diseases affect 3% of the US population, or around The number of people suffering from of chronic diseases such as cancer and autoimmune disorders is anticipated to rise, driving market growth. According to the National Stem Cell Foundation (NSCF), approximately 80 different autoimmune disorders affect around 4% of the world's population. Autoimmune diseases are third among the leading causes of chronic diseases in the US. According to Johns Hopkins Medicine Pathology, autoimmune diseases affect 3% of the US population, or around 10 million people. TPE or therapeutic plasma exchange, is a common treatment for autoimmune diseases. Federal initiatives and reimbursement frameworks are also projected to drive demand throughout the forecast period. Along with these factors, rising product innovations and approvals have fuelled market growth. As a consequence of the aforementioned factors, the apheresis market is likely to develop at a healthy rate over the forecast period.
However, the need for blood components such as plasma, platelets, and red blood cells is increasing consistently due to their important role in medical treatments. Apheresis procedures are crucial in meeting this need by allowing for the effective removal of certain blood components from donors or patients. To maintain and enhance therapeutic effectiveness, precise collection of plasma through apheresis is essential for treating clotting disorders and immune deficiencies in proper manner to avoid cross contamination. Platelets and red blood cells obtained through apheresis are crucial for treating illnesses such as cancer and blood disorders in the same way. The increasing need highlights the importance of apheresis in guaranteeing dependable and readily available blood components for medical therapies.
However, the need for blood components such as plasma, platelets, and red blood cells is increasing consistently due to their important role in medical treatments. Apheresis procedures are crucial in meeting this need by allowing for the effective removal of certain blood components from donors or patients. To maintain and enhance therapeutic effectiveness, precise collection of plasma through apheresis is essential for treating clotting disorders and immune deficiencies in proper manner to avoid cross contamination. Platelets and red blood cells obtained through apheresis are crucial for treating illnesses such as cancer and blood disorders in the same way. The increasing need highlights the importance of apheresis in guaranteeing dependable and readily available blood components for medical therapies.
Versatile Applications with Technological Innovations Propel Market Expansion
Improvements in apheresis technology, including automation, continuous flow systems, and better interface designs, greatly increase the efficiency, safety, and comfort of procedures for patients. Automation speeds up the gathering and handling of blood parts, cutting down on time required and human mistakes. Continuous flow systems improve the extraction process, increasing blood component yield and improving treatment effectiveness. Enhanced interface designs improve usability and patient experience, leading to increased compliance and better outcomes. These advancements in technology enhance clinical results and stimulate market expansion by fulfilling healthcare providers' needs for safer, more effective apheresis options.
The apheresis market is growing by extending its therapeutic applications beyond its conventional uses. Apheresis is increasingly being used to treat a variety of medical conditions, including Guillain-Barré syndrome, immune-mediated glomerulonephritis in nephrology, and different haematological disorders. These developments create fresh prospects for market expansion by tackling unmet healthcare requirements and broadening the range of apheresis procedures beyond traditional uses. This expansion not only improves the choices available for patient care but also highlights the adaptability and efficiency of apheresis in treating complex diseases in various medical fields.
The apheresis market is growing by extending its therapeutic applications beyond its conventional uses. Apheresis is increasingly being used to treat a variety of medical conditions, including Guillain-Barré syndrome, immune-mediated glomerulonephritis in nephrology, and different haematological disorders. These developments create fresh prospects for market expansion by tackling unmet healthcare requirements and broadening the range of apheresis procedures beyond traditional uses. This expansion not only improves the choices available for patient care but also highlights the adaptability and efficiency of apheresis in treating complex diseases in various medical fields.
Recent Trends in Apheresis Market:
- Advancements in automation technologies have led to more automated apheresis systems improving procedure efficiency
- Integration of apheresis systems with electronic health records (EHRs) and data management platforms allows for real-time monitoring
- Apheresis is increasingly being used in novel therapeutic areas such as immunology, oncology and regenerative medicine
- Innovation in device design and technology, including miniaturization, portable systems, and improved safety features
Explore Our Breakthrough Market Segmentation and Personalize it to Meet Your Business Needs…!
A Lack of Skilled Professionals Potentially Affects Market Expansion
The apheresis market is greatly challenged by a lack of skilled professionals who can handle and oversee intricate procedures. Specialized training and expertise are necessary for apheresis including vascular access, patient monitoring, and handling potential complications. A lack of skilled healthcare workers who are proficient in these abilities hinders the growth of apheresis services, especially in areas with few training programs and educational resources available. To tackle this problem, it is essential to invest in specific training programs, cooperate with healthcare and education institutions, and create a welcoming atmosphere to attract and keep skilled apheresis professionals to meet increasing demand and maintain high-quality patient care.
Furthermore, the substantial expense of apheresis equipment and procedures is a major obstacle to accessibility and adoption, particularly in settings with limited resources. Apheresis machines are advanced and expensive, necessitating significant upfront costs and continuous maintenance fees. Furthermore, the costs of the procedures can increase because of the requirement for specific supplies and trained medical staff. The financial obstacles prevent health facilities from obtaining and keeping apheresis technology, thus restricting patient availability for these advanced treatments. Dealing with cost issues includes researching affordable options, discussing pricing agreements, and pushing for financial assistance to guarantee fair access to apheresis treatments globally.
Furthermore, the substantial expense of apheresis equipment and procedures is a major obstacle to accessibility and adoption, particularly in settings with limited resources. Apheresis machines are advanced and expensive, necessitating significant upfront costs and continuous maintenance fees. Furthermore, the costs of the procedures can increase because of the requirement for specific supplies and trained medical staff. The financial obstacles prevent health facilities from obtaining and keeping apheresis technology, thus restricting patient availability for these advanced treatments. Dealing with cost issues includes researching affordable options, discussing pricing agreements, and pushing for financial assistance to guarantee fair access to apheresis treatments globally.
Collaboration for Decentralized Manufacturing & Training Programme Uplifts the Market Escalation
Advancements in the apheresis market to improve technology, broaden therapeutic uses, enhance training, address regulatory hurdles, and reduce costs are crucial. These efforts are vital for improving the effectiveness of treatment, expanding availability, and encouraging creativity in medical treatments that depend on apheresis techniques. For instance, In May 2024, Galapagos NV Blood Centres of America (BCA) announced that they have entered into a strategic collaboration for the decentralized manufacturing of Galapagos’ CAR-T cell therapies through BCA’s network in the U.S. In addition, in May 2023 Terumo Blood and Cell Technologies (Terumo BCT), a medical technology company, launched the first training program of its kind to help cell and gene therapy manufacturers improve their cell collection processes and accelerate the commercialization of therapeutics. The new program trains participants in apheresis. This procedure is used to collect cells, an important step in making cell therapies for patients in need.
Know Your Competitors and Strengthen Market Share Effectively
North America Region Provides A Big Opportunity for Market Players
The apheresis market in North America is defined by strong technological progress, extensive healthcare spending, and a solid regulatory structure. It takes advantage of a robust healthcare system and a high rate of long-term illnesses. The area is also experiencing widespread use of new treatments and an increased focus on individualized healthcare, leading to market expansion and broader utilization across different medical fields. Moreover, collaborations between healthcare providers and research institutions play a role in ongoing progress and the development of novel apheresis technologies. For instance, according to the American cancer Society, in 2024, over 611,000 deaths from cancer are projected for the US. That’s more than 1,600 deaths from cancer each day. The apheresis market in the Asia-Pacific region is set for substantial growth due to higher healthcare spending, escalating rates of chronic illnesses, and enhanced healthcare facilities. Countries such as China, Japan, India, and Australia play a significant role in the increased use of advanced medical technologies like apheresis. The market advantages from a substantial number of patients, increasing elderly population, and increasing knowledge about the therapeutic advantages of apheresis for treating different conditions.
Searching for a Country or Region-Specific Report?
Unlock industry complexities with reports crafted for selected countries and regions at Reduced Cost
The report provides a detailed overview of the apheresis market insights in regions including North America, Latin America, Europe, Asia-Pacific, Oceania, and the Middle East and Africa. The country-specific assessment for apheresis market has been offered for all regional market share, along with forecasts, market scope estimates, price point assessment, and impact analysis of prominent countries and regions. Throughout this market research report, Y-o-Y growth and CAGR estimates are also incorporated for every country and region, to provide a detailed view of the apheresis market. These Y-o-Y projections on regional and country-level markets brighten the political, economic and business environment outlook, which are anticipated to have a substantial impact on the growth of the apheresis market. Some key country and region included in the apheresis market report as follows:
| Regions | Countries |
|---|---|
| North America | United States, Canada |
| Latin America | Brazil, Mexico, Argentina, Colombia, Chile, Rest of Latin America |
| Europe | Germany, United Kingdom, France, Italy, Spain, Russia, Netherlands, Switzerland, Belgium, Sweden, Austria, Norway, Denmark, Finland, Ireland, Czech Republic, Rest of Europe |
| Asia Pacific | China, India, Japan, South Korea, Australia & New Zealand, Singapore, Thailand, Malaysia, Indonesia, Philippines, Rest of Asia Pacific |
| Middle East and Africa | GCC Countries, South Africa, Egypt, Turkey, Morocco, Israel, Iran, Kenya, Nigeria, Rest of MEA |
Apheresis Market Research Report Covers In-depth Analysis on:
- Apheresis market detailed segments and segment-wise market breakdown
- Apheresis market dynamics (Recent industry trends, drivers, restraints, growth potential, opportunities in apheresis industry)
- Current, historical and forthcoming 10 years market valuation in terms of apheresis market size (US$ Mn), share (%), Y-o-Y growth rate, CAGR (%) analysis
- Apheresis market demand analysis
- Apheresis market regional insights with region-wise market breakdown
- Competitive analysis – key companies profiling including their market share, product offerings, and competitive strategies.
- Latest developments and innovations in apheresis market
- Regulatory landscape by key regions and key countries
- Apheresis market sales and distribution strategies
- A comprehensive overview of parent market
- A detailed viewpoint on apheresis market forecast by countries
- Mergers and acquisitions in apheresis market
- Essential information to enhance market position
- Robust research methodology
- Frequently Asked Questions -
What are the key drivers of growth in apheresis market?
Growth drivers include increasing prevalence of chronic diseases, advancements in apheresis technology and rising demand for blood component therapies and diagnostics.
What are the major trends in apheresis market?
Major trends include the development of automated and more efficient apheresis systems, increasing applications in therapeutic areas and expanding use in hospitals and clinics.
What is market outlook for the apheresis industry over the next decade?
The market outlook is positive, with significant growth expected due to technological advancements, increasing adoption of apheresis procedures and rising awareness about blood component therapies.
